Nipocalimab-aah bulk supplier for pharma manufacturers

Nipocalimab-Aah Suppliers & Bulk Manufacturers

Available Forms: Infusion

Available Strengths: 300 mg/1.62 mL, 1200 mg/6.5 m

Reference Brands: Imaavy (USA/EU)

Category: Neurology

Nipocalimab-aahu is a fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), reducing circulating IgG and harmful autoantibodies. It is used for the treatment of generalized myasthenia gravis in antibody-positive patients. By lowering IgG levels, it helps improve muscle strength and reduce disease activity without broad immunosuppression. It is given as an intravenous infusion under medical supervision. Patients are monitored for infusion reactions and infection risks.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Nipocalimab-Aah? List it or send an offer →

Product Description:

Nipocalimab is a fully human monoclonal antibody against the neonatal Fc receptor. FcRn normally rescues IgG from lysosomal degradation, which is why IgG has such a long half-life. Blocking it accelerates breakdown of all IgG, including the pathogenic autoantibodies that drive generalised myasthenia gravis, lowering total IgG by roughly three quarters. It treats the disease by removing the antibodies rather than suppressing the cells that make them.

It is given as an intravenous infusion, with a loading dose followed by maintenance every two weeks, and is approved for generalised myasthenia gravis in adults and adolescents who are antibody-positive — the approved population spans acetylcholine receptor and MuSK antibodies, which is broader than some earlier FcRn blockers. Because it reduces all IgG, infection risk rises, live vaccines are avoided during treatment, and vaccination schedules are reviewed before starting.

Sourcing notes. Originator biologic, on patent, no biosimilar. Approved in the US in 2025 and by the European Commission later that year; registration elsewhere is still under way. It competes with other FcRn blockers and complement inhibitors, so formulary position varies by market. Supply is through authorised distribution under cold chain, and use is initiated in specialist neuromuscular centres.

How Nipocalimab-Aah is supplied today, and licensing ahead of patent expiry

Nipocalimab-Aah is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Nipocalimab-Aah, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Nipocalimab-Aah supply →

Back to Listing

Frequently Asked Questions

Nipocalimab-aahu is used for the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients aged 12 years and older who are positive for anti-AChR or anti-MuSK antibodies.

It is made from a fully human IgG1λ monoclonal antibody designed to block the neonatal Fc receptor (FcRn), leading to a reduction in circulating IgG levels.

The trade name is Imaavy.

It is manufactured and marketed by Janssen Biotech, Inc., a part of Johnson & Johnson.

The generic name is nipocalimab-aahu.

The brand name is Imaavy.

The drug substance is manufactured by WuXi Biologics in China, and the final finished product is filled and packaged by Vetter Pharma in Germany.

Imaavy (Nipocalimab) is developed and sold by Johnson & Johnson. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.